Homology Medicines

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.

Homology Medicines, established in 2015 and headquartered in United States, North America., specializes in investments across Biotechnology, Health Care, Medical, Therapeutics, Information Technology, Software, Financial Services, Venture Capital, Finance, CleanTech. The organization boasts a portfolio of 1 investments, with an average round size of $42.0M and 1 successful exits. Their recent investments include Q32 Bio, OUP (Osage University Partners), Atlas Venture, Bristol-Myers Squibb, Abingworth. The highest investment round they participated in was $5.7B. Among their most notable exits are Q32 Bio and OUP (Osage University Partners). Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.